Share

We have had an amazing response to the NAD+ Mouse Project currently fundraising on Lifespan.io. The generous double fund matches totaling 20k were triggered in the first two days of the launch, taking the total funding to a stunning $36,000!

This means that the initial project will go ahead!

The initial stage of the experiment can now go ahead as planned. The first stage of the NAD+ mouse project will see the research team testing the NAD+ precursor nicotinamide mononucleotide (NMN) on a special kind of mouse that experiences rapid aging. This mouse is called ICE (Induced Changes in Epigenome), and because it has accelerated aging due to modifications to its gene expression, initial results will be much faster than waiting to get them from normally aging mice, which live a few years.

Alongside the ICE mice, normally aging mice will also be given NMN, and their responses will be compared to the ICE mice for further validation. We anticipate having results within six months of the project launching. This is an important step of the experiment because ICE mice may turn out to be a superior model of aging than current progeric strains of mice; this would give researchers a better way to obtain initial results for aging research more quickly.

Can we reach $45k to unlock the next project goal?

Of course, there is nothing as good as testing therapies on normally aging mice, and this is why the next stage of the project is arguably even more important. The first stretch goal of the project is $45,000 and will allow the team to expand the scope of the experiment and extend the study to up to a year. This would give the team more time to test how NMN performs against reversing aging and the longer-term effects of using it on both the ICE mice and their normally aging siblings. The longer experiment would also mean that more cognitive, behavioral and physiological tests could be carried out to learn even more about the effects of NMN. This would help to determine the efficacy of NMN in preventing or even reversing age-related cognitive and physical decline.

A huge thank you to everyone who has supported the project so far!

We would like to take the opportunity to thank everyone who has supported the project so far and for the enthusiasm that many members of our community have shown for the project. We offer special thanks to the two anonymous donors who created the matching funds and to James Johnson, who donated a staggering $10,000 to the campaign, helping us to smash the initial funding goal in just two days!

Thanks to our community, we have already raised an amazing $36,000, and if we can reach $45,000, Dr. Sinclair and his team gain the opportunity to do some very interesting science. This project potentially has large implications for aging research and could help push the development of therapies that truly address the aging processes and make such therapies a reality in the near future.

The researchers at the Sinclair Lab, Harvard, and the team at Lifespan.io thank you!

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD